A retrospective cohort study of patients with advanced breast (n [ 874) and ovarian cancer (n [ 170) was conducted to evaluate the association between relative dose intensity of first-line intravenous myelosuppressive chemotherapy and overall survival. Factors associated with increased mortality were identified for both cancer types. Knowledge of potential risk factors may help inform the effect of dose modification strategies on mortality. Background: The effects of chemotherapy dose intensity on patient outcomes in advanced cancer are not well understood. We studied the association between chemotherapy relative dose intensity (RDI) and overall survival (OS) among patients with advanced breast or ovarian cancer. Patients and Methods: This retrospective cohort study included adults with advanced breast or ovarian cancer who received first-line myelosuppressive chemotherapy (January 2007 to December 2010) in US Oncology Network community practices. Dose delays ! 7 days, dose reductions ! 15%, and RDI relative to standard regimens were described. OS was measured by the Kaplan-Meier method and Cox proportional hazards models. Results: Among 874 patients with advanced breast cancer, 33.2% experienced dose delays ! 7 days, 48.7% experienced dose reductions ! 15%, and 38.9% had RDI < 85%. In the multivariable Cox proportional hazards model, Eastern Cooperative Oncology Group performance status 1/2 versus 0 (hazard ratio [HR] ¼ 1.45; 95% confidence interval [CI], 1.15-1.82) and triple-negative status (HR ¼ 3.14; 95% CI, 1.15-8.62) were significantly associated with mortality. Among 170 patients with advanced ovarian cancer, 43.5% experienced dose delays ! 7 days, 48.2% experienced dose reductions ! 15%, and 46.5% had RDI < 85%. In the multivariable Cox proportional hazards model, dose reductions ! 15% (HR ¼ 1.94; 95% CI, 1.09-3.46) and other tumor histology (vs. nonserous adenocarcinoma; HR ¼ 3.55; 95% CI, 1.38-9.09) were significantly associated with mortality. Conclusion: Dose delays, dose reductions, and reduced RDI were common. In advanced breast cancer, health status and triple-negative disease were significantly associated with mortality. In advanced ovarian cancer, dose reductions and tumor histology were significantly associated with mortality. These results can help identify potential risk factors and characterize the effect of chemotherapy dose modification strategies on mortality.
Introduction
Myelosuppressive chemotherapy regimens are commonly used to treat breast and ovarian cancers in US clinical practice.
1,2 However, adverse drug effects such as febrile neutropenia can lead to dose delays and/or reductions. 3, 4 In the adjuvant setting, the importance of receiving full-dose chemotherapy on schedule (ie, high relative 1 Virginia Cancer Specialists, US Oncology Network, Arlington, VA dose intensity [RDI]) 5, 6 has been well established. High RDI is associated with improved survival, especially for patients with earlystage breast cancer and non-Hodgkin lymphoma. 3, [7] [8] [9] [10] [11] [12] In advanced disease, clinical goals differ and include control of cancer growth, symptom management, and extension of life. 13 Chemotherapy dose delays and reductions are common in advanced disease to manage chemotherapy-associated toxicities; 14, 15 however, the effect of RDI on long-term outcomes such as overall survival (OS) in the realworld setting is not well understood. Calculating RDI can be challenging in the advanced-disease setting because standard chemotherapy regimens are not well defined, and chemotherapy is often given until disease progression or toxicity precludes continued treatment (therefore, no "standard" regimen may be planned). 16 Despite the difficulties, studies have
shown an association between high RDI and improved survival in advanced disease. In advanced breast cancer, a pooled analysis of 3 randomized clinical trials showed that RDI < 85% was associated with worse OS. 17 In advanced ovarian cancer, a meta-analysis of 21
randomized clinical trials and 17 cohort studies showed that higher dose intensity was associated with improved survival, 4 and a multicenter retrospective study showed that RDI < 85% was associated with worse OS. 18 There is limited information on the impact of RDI on short-and long-term outcomes in the advanced cancer setting. To better understand the effect of chemotherapy dose intensity in the advanced cancer setting, we studied dose delays, dose reductions, RDI, and the association between chemotherapy intensity and OS among patients with advanced breast, ovarian, or lung cancer. Here we report results from patients with breast cancer; results from patients with ovarian cancer are also included here given the small cohort size. Results from patients with lung cancer have been reported separately. 19 
Patients and Methods

Study Design and Data Source
This was a retrospective cohort study of patients diagnosed with advanced breast, ovarian, or lung cancer; only advanced breast and ovarian cancer are included in this analysis. Data were extracted from the iKnowMed (iKM; McKesson Specialty Care Solutions/US Oncology, The Woodlands, TX) database, a web-based oncologyspecific electronic health record (EHR) system that includes > 16 million patient records and 900 oncologist users in the United States. The protocol was submitted to the institutional review board for review and was exempted.
The unit of analysis was the first-line chemotherapy course (index course [ie, first observed intravenous myelosuppressive chemotherapy course]) for each patient. The actual delivered number of chemotherapy cycles, actual delivered dose in each cycle, and actual length of each cycle were recorded in iKM. The index course was assumed to be terminated after a chemotherapy administration if there was no evidence of receipt of any subsequent chemotherapy administration within 60 days after that administration, or if death or unplanned regimen change occurred. The termination date of the index course was assumed to be the date of last chemotherapy administration plus the standard cycle length (according to the corresponding standard regimen as identified based on first-cycle agents), death date, or date of unplanned regimen change, whichever occurred first.
Patients
This study included patients ! 18 years old diagnosed with advanced breast or ovarian cancer, who received first-line intravenous myelosuppressive chemotherapy between January 2007 and December 2010 from oncology practices using the full EHR capacities of iKM and who had ! 4 visits in the US Oncology Network during the study period. Patients were excluded if they were enrolled in clinical trials for cancer treatment at time of enrollment; had a diagnosis of any primary cancer other than breast or ovarian cancer; received only nonmyelosuppressive agents during cycle 1; or received any oral myelosuppressive agents during the index course.
Patients were monitored for 6 months from initiation of chemotherapy for estimation of RDI and incidence of RDI < 85%, dose delays, and dose reductions, colony-stimulating factor (CSF) and prophylactic antimicrobial use, and grade 3/4 neutropenia. Patients were followed until death or last visit date available to estimate OS.
Study Outcomes
Data on planned chemotherapy, planned chemotherapy dose and schedule, planned cycle length, actual chemotherapy, actual chemotherapy dose and schedule, and actual cycle length were extracted from the iKM database. Only chemotherapy regimens with data for > 100 patients were included in most analyses, and smaller subgroups were included for key regimens.
Grade 3/4 neutropenia was defined as absolute neutrophil count (ANC) < 1000 cells/mm 3 . Prophylaxis with CSF was defined as use by day 5 of the chemotherapy cycle. Primary prophylaxis was defined as first use in chemotherapy cycle 1; secondary prophylaxis was defined as first use in any subsequent cycle. Reactive treatment was defined as use after day 5 of the chemotherapy cycle. The analysis included only CSF use that was documented in the iKM database.
Chemotherapy dose delays, dose reductions, and RDI (Supplemental Table 1 in the online version) were evaluated against standard regimens (Supplemental Table 2 in the online version). Standard regimen information was extracted from the National Comprehensive Cancer Network guidelines current at the time of this analysis 20 and from published efficacy and outcome data from phase 3 clinical trials. When dosing was based on weight, actual weight was used. Dose delays and reductions were only evaluated for intravenously administered myelosuppressive agents. Dose delay was defined as a delay ! 7 days in any given cycle from the standard regimen. Dose reduction was defined as a decrease in chemotherapy dose ! 15% relative to standard (mg/m 2 ) for ! 1 myelosuppressive agent in any given cycle. Termination date of the index course was assumed to be the date of last chemotherapy administration plus standard cycle length (according to the corresponding standard regimen as identified based on first-cycle agents), date of death, or date of regimen change, whichever occurred first. Chemotherapy RDI was defined as the ratio of delivered dose intensity to standard dose intensity.
Dose delays, dose reductions, and RDI were evaluated over the first 6 months for each myelosuppressive agent administered as part of the standard chemotherapy regimen. Doses beyond 6 months were not considered. For regimens containing multiple myelosuppressive agents, RDI was defined as the mean value of the individual RDIs for each myelosuppressive agent in the regimen. If the dose or number of cycles received in 6 months by a patient was higher than standard, the RDI value of the chemotherapy course may have exceeded 100%. RDI < 85% is considered a clinically important reduction in the standard chemotherapy regimen 12 and was used as a threshold to define reduced RDI. OS was defined as the interval between initiation of the first-line chemotherapy regimen for advanced disease and death or last follow-up. Only deaths were included in the OS analysis; patients who did not have the event were censored on the follow-up end date. Data on eligible patients were collected up to December 2010. The death event was identified by the Social Security Death Index (assessed from January 2007 to December 2010), supplemented by iKM; patients without the event were censored at the date of last observed visit.
Statistical Analysis
No formal sample size calculations were performed. Descriptive analyses were conducted for all study variables. Unadjusted survival analyses with Kaplan-Meier estimator and log-rank tests were conducted to compare OS between patients with different dosing schedules. Univariable Cox regression analyses were conducted to evaluate the hazard ratio (HR) for each covariate, and multivariable Cox models were used to adjust for covariates. Proportional hazards models were visually assessed, and multicollinearity and model consistency were manually evaluated.
Univariable Models. For breast and ovarian cancers, the following variables were examined independently as a predictor of survival: dose delay ! 7 days (vs. < 7); dose reduction ! 15% (vs. < 15%); RDI < 85% (vs. ! 85%); age at first visit; Eastern Cooperative Oncology Group performance status (ECOG PS) 1 or 2 (vs. 0); baseline ANC < 1000 (vs. ! 1000); ! 1 comorbidity (vs. 0 comorbidities); and hemoglobin < 12 g/dL (vs. ! 12). Breast cancer univariable models also examined estrogen receptor (ER)-negative and progesterone receptor (PR)-negative (vs. ER-positive/PR-positive) and human epidermal growth factor receptor 2 (HER2)-negative (vs. HER2-positive). Ovarian cancer univariable models also examined body surface area (BSA) < 2 m 2 (vs. ! 2 m 2 ) and tumor histology (serous vs. nonserous adenocarcinoma; other vs. nonserous adenocarcinoma).
Multivariable Models. Multivariable Cox regression models included variables of significant and marginally significant (P < .10) univariable predictors in combination with clinically meaningful variables and were validated using backward selection with an entry criteria of P < .25 and a stay criteria of P < .15. The best models were selected based on the lowest Akaike Information Criterion. The final multivariable model was refit using the significant predictors (P < .05); patients with missing data for these variables were excluded.
Results
Breast Cancer
Patient Demographics and Disease Characteristics. This study included 874 patients with advanced breast cancer. Mean (SD) age was 60.6 (12.5) years, and 37.4% were ! 65 years old. A total of 129 patients (14.8%) had a BSA > 2 m 2 , and 317 (36.3%) had an ECOG PS ! 1 (Table 1) . Overall, 601 patients (68.8%) had ER-positive breast cancer, 484 (55.4%) had PR-positive breast cancer, and 96 (11.0%) had tumors that overexpressed HER2. The most common chemotherapy regimens were paclitaxel/bevacizumab every 4 weeks 1 (q4w; 364 patients, 41.6%), albumin-bound paclitaxel every 3 weeks (q3w; 178 patients, 20.4%), and weekly Table 4 in the online version). Mean (SD) RDI was 96.9% (22.4%) with q3w docetaxel, 89.9% (20.4%) with q4w paclitaxel/bevacizumab, 79.9% (20.5%) with weekly vinorelbine, and 72.6% (17.6%) with q4w carboplatin/paclitaxel (Supplemental Table 3 in the online version).
Neutropenia and Supportive Care. Among 655 patients with evaluable ANC data, 168 (25.6%) experienced documented grade 3/4 neutropenia. Despite this relatively high rate of neutropenia, febrile neutropenia prophylaxis with CSFs or antimicrobials was uncommon. Only 50 patients (5.7%) received documented primary prophylaxis with CSFs, 31 (3.6%) received documented primary prophylaxis with oral antimicrobials; 27 (3.1%) received documented secondary prophylaxis with CSFs, and 73 (8.4%) received documented secondary prophylaxis with oral antimicrobials.
Overall Survival. Patients who received vinorelbine (n ¼ 55) were excluded because of small sample size and varied dosing of this regimen. Overall, 819 patients with breast cancer and 485 deaths (59.2%) were included in the OS analysis.
Median OS was 2.9 (95% CI, 2.6-3.5) years, and median follow-up time was 2.8 (25th-75th percentile: 1.0-4.8) years. After stratification by measures of chemotherapy intensity (dose delays < 7 vs. ! 7 days, dose reductions < 15% vs. ! 15%, and RDI < 85% vs. ! 85%), significant differences in OS were observed only for dose reductions ( Figure 1A ; log-rank P ¼ .0195). Median (95% CI) OS was 2.3 (1.9-2.9) years for patients with dose reductions ! 15% and 3.7 (3.2-4.2) years for patients with reductions < 15%.
In the univariable analysis of OS, dose reductions ! 15% (HR ¼ 1.24; 95% CI, 1.03-1.48; P ¼ .020), older age (HR ¼ 1.01; 95% CI, 1.00-1.02; P ¼ .004), ECOG PS 1 versus 0 (HR ¼ 1.45; 95% CI, 1.19-1.76; P < .001), ! 1 comorbidity (HR ¼ 1.24; 95% CI, 1.02-1.51; P ¼ .032), hemoglobin < 12 g/dL (HR ¼ 1.35; 95% CI, 1.10-1.64; P ¼ .004), and HER2-negative status (HR ¼ 1.50; 95% CI, 1.06-2.12; P ¼ .022) were significantly associated with increased risk of death (Supplemental Table 5 in the online version). Other measures of chemotherapy intensity (RDI and dose delays) were not significantly associated with OS.
The multivariable model included the 492 patients with complete data for ECOG PS, hemoglobin, ER status, PR status, and HER2 status. Many patients with breast cancer in the full cohort were missing data on hemoglobin or one of the hormone receptor variables ER, PR, or HER2 (Table 1) . Patients in the full cohort were compared with those in the reduced cohort used in the multivariable models to investigate whether the reduced cohort was different in any way compared with the full cohort in terms of RDI, dose delay, dose reduction, ECOG PS, ER/PR status, HER2 status, ANC < 1000, hemoglobin, and comorbidities. No significant differences in median survival time or baseline demographics were seen between the full population used in the univariable analysis and the population used in the multivariable analysis, with the exception of comorbidities; significantly fewer patients had no comorbidities in the population used for the multivariable analysis (66.9% vs. 73.3%, chi-square P ¼ .0137). In the multivariable analysis, ECOG PS 1/2 versus 0 (HR ¼ 1.45; 95% CI, 1.15-1.82; P ¼ .002) and triple-negative status (triple-negative vs. any ER, PR, or HER2-positive; HR ¼ 3.14; 95% CI, 1.15-8.62; P ¼ .026) were significantly associated with increased risk of death (Table 2 ). , and 122 (71.8%) had an ECOG PS ! 1 ( Table 1 ). The only regimen with > 100 patients was q3w carboplatin/paclitaxel. Dose Delays, Dose Reductions, and RDI. Dose delays, dose reductions, and reduced RDI were also common in ovarian cancer patients. A total of 43.5% patients experienced a dose delay ! 7 days, and 48.2% experienced a dose reduction ! 15%. Mean (SD) RDI was 82.4% (26.7%), and 46.5% of patients received an RDI < 85%. Dose delays and reductions were common even among young patients, with approximately half of patients 18 to 49 years old having a dose delay (50.0%), dose reduction (44.4%), and/or reduced RDI (55.6%). Reduced RDI was also common regardless of BSA (59.1% for BSA > 2 m 2 and 45.7% for BSA 2 m 2 ) or ECOG PS (56.3% for ECOG PS ! 2% and 47.4% for ECOG PS 0) (Supplemental Table 6 in the online version).
Neutropenia and Supportive Care. Documented grade 3/4 neutropenia incidence was low (9/164, 5.5%, patients with baseline ANC data). Thirty-four patients (20.0%) received documented CSF primary prophylaxis; 36 (21.2%) received documented CSF secondary prophylaxis. No patient received documented prophylaxis with antimicrobials.
Overall Survival. All 170 patients with advanced ovarian cancer, 73 (42.9%) of whom died, were included in the OS analysis. When OS was stratified by measures of chemotherapy intensity (RDI < 85% vs. ! 85%, dose delays < 7 vs. ! 7 days, and dose reductions < 15% vs. ! 15%), significant differences in OS were observed only for dose reductions ( Figure 1B ; log-rank P ¼ .0114). Median (95% CI) OS was 2.3 (1.7-4.1) years for patients with dose reductions ! 15% and 3.2 (3.0-not reached) years for patients with reductions < 15%.
In the univariable analysis, dose reductions ! 15% (HR ¼ 1.80; 95% CI, 1.14-2.87; P ¼ .013) and older age (HR ¼ 1.02; 95% CI, 1.00-1.04; P ¼ .050) were significantly associated with increased risk of death (Supplemental Table 7 in the online version). Other measures of chemotherapy intensity (RDI and dose delays) were not significantly associated with OS.
The multivariable model included the 123 patients with complete data for dose reductions, hemoglobin, and tumor histology. In the multivariable analysis, dose reductions ! 15% (HR ¼ 1.94; 95% CI, 1.09-3.46; P ¼ .025) and other tumor histology (vs. nonserous adenocarcinoma; HR ¼ 3.55; 95% CI, 1.38-9.09; P ¼ .008) were significantly associated with increased risk of death (Table 3) .
Discussion
Real-world chemotherapy dosing patterns for patients with advanced breast and ovarian cancer are not well understood. This study used the large iKM EHR database to describe treatment patterns and identify factors that affect OS among patients with advanced breast and ovarian cancer in clinical practice. Dose delays and reductions were common, and given the lack of curative intent, reduced RDI was common, with more than one third of patients with advanced breast cancer and nearly half of patients with advanced ovarian cancer having RDI < 85%. Interestingly, dose delays, dose reductions, and reduced RDI were common even among younger patients (ie, 18-49 years old), although the reasons (eg, work schedules, family responsibility, travel) may differ from those typically seen for older patients (eg, toxicity, comorbidities).
In patients with breast cancer, treatment patterns varied widely across different types of chemotherapy regimens. For example, nearly all patients receiving carboplatin/paclitaxel q4w had dose reductions but dose delays were fairly uncommon, and this regimen had the lowest mean RDI observed. Conversely, patients receiving docetaxel q3w had dose delays and reductions that were far less frequent, and this regimen had the highest mean RDI observed.
High rates of severe neutropenia were observed in patients with breast cancer; however, primary prophylaxis with CSF, which can help sustain chemotherapy dose intensity, 3 was only documented for 5.7% of patients with advanced breast cancer, potentially affecting mortality findings. By contrast, low rates of documented severe neutropenia were observed in patients with ovarian cancer and ! 20% of patients with ovarian cancer received primary and secondary prophylaxis with CSF. The effects of chemotherapy intensity varied among different cancer types. In breast cancer, dose reductions were significantly associated with worse OS in the univariable analysis, but dose reductions were not significant in the multivariable analysis. In ovarian cancer, dose reductions were significantly associated with worse OS in both the univariable and multivariable analyses. These results suggest that maintenance of chemotherapy dose may provide a survival benefit independent of dose timing or overall RDI, at least in ovarian cancer.
This study adds to a growing body of knowledge of the effect of RDI and other measures of dose intensity on OS. In both advanced breast and ovarian cancer, reduced RDI has been associated with worse outcomes. In advanced breast cancer, RDI < 85% was associated with shorter OS in a pooled analysis of 933 patients from 3 randomized controlled clinical trials who were receiving anthracycline/taxane-based regimens. 17 In advanced ovarian cancer, 3 studies have shown an association between dose intensity and survival, at least for some chemotherapy regimens. In a meta-analysis of 4118 patients with advanced ovarian cancer from 38 studies (21 randomized clinical trials and 17 cohort studies), dose intensity correlated with improved survival when all chemotherapy agents in the regimen were analyzed, but no association was seen when only the dose intensity of the platinum-based agents was investigated. 4 Furthermore, in a multicenter retrospective study of 325 patients with advanced ovarian cancer receiving platinum-based agents, RDI < 85% was associated with worse OS. 18 Last, in a phase 3, openlabel, randomized study of dose-dense paclitaxel plus carboplatin in patients with advanced ovarian cancer, dose-dense treatment improved OS compared with the conventional regimen, but at the expense of increased toxicity. 21 RDI was not reported directly in this study; however, the dose-dense treatment regimen increased the total dose delivered to the patients over time. 21 These data indicate that the potential impact observed on mortality from increasing dosing must be balanced against the potential for increased toxicity. Several factors may explain why RDI < 85% was not significantly associated with OS in our study. Although no marked differences were observed in the data collected, patients who received RDI ! 85% may have had other clinical differences from patients who received a reduced RDI that were not captured. Additionally, a large proportion of the previous data was derived from clinical trials, and these patients may differ from those treated in the real-world setting. Results may also differ based on chemotherapy regimen or disease type. Furthermore, sample size may have been limiting for examining multivariable predictors of survival in the ovarian cancer cohort. Differences among studies must be interpreted with caution because of variability in RDI calculation methods. More robust and consistent analysis and reporting of dose delays, dose reductions, and RDI in clinical trials as well as retrospective studies are needed to better understand the effects of RDI on patient outcomes. Moreover, retrospective analysis can be challenging in this patient population as even with multivariable modeling, biases based on confounding may exist as dose reduction and delays inherently occur more frequently in a population at higher risk for complications.
In addition to dose reductions, several other factors were found to be associated with OS. ECOG PS ! 1 and triple-negative status were significantly associated with increased risk of death among patients with advanced breast cancer. Other tumor histology (other epithelial and ovarian malignancies vs. nonserous adenocarcinoma) was significantly associated with increased risk of death among patients with advanced ovarian cancer. These findings are generally consistent with the literature. Higher ECOG PS is a well-established risk factor for worse survival in multiple tumor types, 22, 23 and patients with ER/PR-positive and HER2-negative breast cancer tended to have better outcomes than patients with triple-negative breast cancer. 24, 25 HER2 overexpression is a negative prognostic factor for survival in patients with metastatic breast cancer; in this study, OS was not significantly different between patients who were HER2-negative versus HER2-positive, possibly because the study was not powered to detect such differences. In advanced ovarian cancer, patients with high-grade serous carcinomas, more advanced stage disease, and suboptimal surgical cytoreduction generally have worse prognoses. Together, these analyses may begin to identify groups of patients who are at risk for worse survival and treatment patterns that best support patient outcomes. Study limitations include the retrospective nature of the analysis. Given the retrospective design, missing data for the multivariable analysis could not be reconciled because data were limited to what healthcare providers entered into the EHR. The study was also limited by the relatively short follow-up time for patients with breast cancer. Additionally, some variables, such as comorbidities or other factors known to be associated with OS, may not be fully captured. There may also be unobserved confounding. Specifically, dose reductions may confound OS by being present in a less healthy cohort of patients. Further research is needed to explore the effect of comorbidities, hospitalization, cancer type, and treatment regimen on the association between RDI and OS. Lastly, progression-free survival was originally listed as a secondary objective but was not analyzed because limits of the structured EHR database would have required manual patient chart review.
Conclusion
Dose delays, dose reductions, and reduced RDI were common when treating patients with advanced breast and ovarian cancer. The impact of dose intensity on OS may depend on chemotherapy regimen or tumor type. In patients with advanced breast cancer, ECOG PS and triple-negative disease were significantly associated with mortality. In patients with advanced ovarian cancer, dose reductions and tumor histology were significantly associated with mortality. As higher RDI can result in greater toxicity, treatment should be a balance between OS and quality of life, especially with advanced disease. Thus, a better understanding of factors that affect OS can aid physician and patient decision making.
Clinical Practice Points
Adverse effects of myelosuppressive chemotherapy regimens used to treat breast and ovarian cancers in US clinical practice can lead to chemotherapy dose delays and/or dose reductions. Although the importance of receiving full-dose chemotherapy on schedule (ie, high RDI) is well established in the adjuvant
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Clinical Breast Cancer October 2018 -385 setting, the effect of RDI on long-term outcomes in the realworld setting is not well understood. We retrospectively studied the association between chemotherapy dose intensity and long-term outcomes by analyzing data from a web-based oncology-specific EHR system with > 16 million patient records and 900 oncologist users in the United States to describe treatment patterns and identify factors that affect OS among patients with advanced breast and ovarian cancer treated in community oncology practices. The results of our study showed that chemotherapy dose delays, dose reductions, and reduced RDI were common in patients with advanced breast and ovarian cancer in clinical practice; in patients with breast cancer, ECOG PS and triple-negative status were associated with mortality, and in patients with ovarian cancer, chemotherapy dose reductions ! 15% and other tumor histology (vs. nonserous adenocarcinoma) were associated with mortality. These findings may help identify potential risk factors and characterize the effect of chemotherapy dose modification strategies on mortality.
